<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT00185848</url>
  </required_header>
  <id_info>
    <org_study_id>BRNCNS0003</org_study_id>
    <secondary_id>95908</secondary_id>
    <secondary_id>BRNCNS0003</secondary_id>
    <nct_id>NCT00185848</nct_id>
  </id_info>
  <brief_title>Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis</brief_title>
  <official_title>Imaging the Biodistribution of the Positron Emission Tomography Reporter Probe, [18F]FHBG, in Humans.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether [18F]FHBG is suitable for use as an
      imaging probe in cancer or rheumatoid arthritis patients enrolled in cell or gene therapy
      trials.  In this phase 1 study we will assess the safety and biodistribution of [18F]FHBG in
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The success of cell and gene therapy depends on specific targeting of the therapeutic gene
      or cell that is administered to the patient.  Our goal is to develop an imaging method to
      non-invasively monitor the location of the therapeutic gene or cell.  Imaging should help in
      the design of better protocols and potentially reduce side-effects of cell and gene therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The primary endpoint of the study for each patient is acquisition of PET/CT image.</measure>
    <time_frame>Time of scan</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collection of vital signs, EKG, blood chemistry and CBC data</measure>
    <time_frame>day 1, 2 and 8.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Brain Cancer</condition>
  <condition>Arthritis, Rheumatoid</condition>
  <condition>Central Nervous System Neoplasms</condition>
  <condition>Glioma</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>[18F]FHBG</intervention_name>
    <description>&lt; 7mCi and 2 ug, iv</description>
    <other_name>18F-FHBG</other_name>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Patients with intact or surgically removed gliomas.Patients with Rheumatoid Arthritis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Rheumatoid Arthritis.Patients with intact or surgically removed gliomas.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Clinical diagnosis of brain tumor or rheumatoid arthritis

        Exclusion Criteria:

        - Below 18 years of age
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjiv Sam Gambhir M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shahriar Yaghoubi</last_name>
    <phone>(650) 725-6070</phone>
    <email>syaghoub@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahriar Yaghoubi</last_name>
      <phone>650-725-6070</phone>
      <email>syaghoub@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Shahriar Yaghoubi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahriar Shah Yaghoubi, Ph.D</last_name>
      <phone>650-725-6070</phone>
      <email>syaghoub@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lindee Burton</last_name>
      <phone>(650) 725-4712</phone>
      <email>lburton@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sanjiv Sam Gambhir M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael L Goris</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Andrew Quon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Lawrence Recht</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shahriar Shah Yaghoubi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yaghoubi S, Barrio JR, Dahlbom M, Iyer M, Namavari M, Satyamurthy N, Goldman R, Herschman HR, Phelps ME, Gambhir SS. Human pharmacokinetic and dosimetry studies of [(18)F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. J Nucl Med. 2001 Aug;42(8):1225-34.</citation>
    <PMID>11483684</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 6, 2013</lastchanged_date>
  <firstreceived_date>September 12, 2005</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
